Litigation Details for Bristol-Myers Squibb Company v. Mylan Pharmaceuticals Inc. (N.D.W. Va. 2017)

Bristol-Myers Squibb Company v. Mylan Pharmaceuticals Inc. (N.D.W. Va. 2017)

Docket	1:17-cv-00055	Date Filed	2017-04-12
Court	District Court, N.D. West Virginia	Date Terminated	2018-12-26
Cause	35:271 Patent Infringement	Assigned To	Irene Patricia Murphy Keeley
Jury Demand	None	Referred To	Robert W. Trumble
Patents	6,967,208; 9,326,945
Link to Docket	External link to docket

Details for Bristol-Myers Squibb Company v. Mylan Pharmaceuticals Inc. (N.D.W. Va. 2017)

Date Filed	Document No.	Description	Snippet	Link To Document
2017-04-12				External link to document

Bristol-Myers Squibb v. Mylan Pharmaceuticals: Eliquis Patent Litigation Summary and Analysis

Last updated: October 6, 2026

Bristol-Myers Squibb Company v. Mylan Pharmaceuticals Inc., No. 1:17-cv-00055-RGA, was a Hatch-Waxman action in the U.S. District Court for the District of Delaware involving Mylan’s proposed generic version of Eliquis, the anticoagulant apixaban. The case focused principally on U.S. Patent No. 9,326,945, which covered pharmaceutical compositions containing apixaban. The district court held the asserted claims invalid as obvious, and the Federal Circuit affirmed. The decision weakened Bristol-Myers Squibb’s ability to use the formulation patent to delay generic apixaban entry, although other Eliquis patent and regulatory barriers remained relevant to market timing. (Bristol-Myers Squibb Co. v. Mylan Pharmaceuticals Inc., 2023)

What drug and regulatory filing were at issue?

The dispute concerned Eliquis tablets, which contain apixaban and are marketed by Bristol-Myers Squibb and Pfizer for prevention and treatment of thromboembolic conditions, including stroke prevention in patients with nonvalvular atrial fibrillation and treatment or prevention of deep-vein thrombosis and pulmonary embolism.

Mylan filed an abbreviated new drug application under the Hatch-Waxman Act seeking approval for generic apixaban tablets. Its filing included Paragraph IV certifications challenging the validity, enforceability, or infringement of Eliquis patents listed in the FDA’s Approved Drug Products with Therapeutic Equivalence Evaluations, commonly known as the Orange Book.

Item	Detail
Reference drug	Eliquis
Active ingredient	Apixaban
Reference applicant	Bristol-Myers Squibb and Pfizer
Generic applicant	Mylan Pharmaceuticals Inc.
Court	U.S. District Court for the District of Delaware
Civil action	No. 1:17-cv-00055-RGA
Filing date	January 2017
Statutory framework	Hatch-Waxman Act
Generic filing	Mylan ANDA for apixaban tablets
Principal patent on appeal	U.S. Patent No. 9,326,945
Federal Circuit appeal	2022-2090
Federal Circuit decision	June 16, 2023

What patents protected Eliquis in the Mylan litigation?

The case involved Eliquis patent rights listed by Bristol-Myers Squibb in connection with apixaban. The key patents were the compound patent and the later formulation patent.

U.S. Patent No. 6,967,208

The ’208 patent covered apixaban and related compounds. It was the principal composition-of-matter patent for Eliquis. The patent had an original expiration date in December 2026, subject to applicable patent-term adjustments and regulatory exclusivity calculations.

The compound patent provided the strongest exclusionary right because it covered the active pharmaceutical ingredient itself rather than a particular tablet formulation. A generic applicant that infringes a valid and enforceable compound patent generally cannot commercially market the covered product before expiration unless it obtains a license or prevails in litigation.

U.S. Patent No. 9,326,945

The ’945 patent covered pharmaceutical compositions containing apixaban. The asserted claims addressed tablet compositions and related formulation characteristics, including the use of specified excipients and composition parameters.

The patent had a later nominal expiration date than the ’208 patent. Its commercial purpose was to extend protection beyond the compound patent by covering the marketed dosage form. The Mylan litigation tested whether that additional protection was patentably distinct or obvious in view of the prior art.

Patent	General subject matter	Strategic role
’208 patent	Apixaban compound and related compounds	Core active-ingredient protection
’945 patent	Apixaban pharmaceutical compositions	Formulation and dosage-form protection

Patent expiration dates should be read together with patent-term adjustment, pediatric exclusivity, terminal disclaimers, Orange Book updates, and any settlement or license rights. The litigation outcome did not itself eliminate every potential barrier to generic entry.

What did Bristol-Myers Squibb allege against Mylan?

Bristol-Myers Squibb alleged that Mylan’s proposed generic apixaban products would infringe the asserted Eliquis patents. The company sought the standard Hatch-Waxman remedy: an order prohibiting FDA approval of Mylan’s ANDA until the expiration of the patents or other resolution of the infringement dispute.

Mylan challenged the patents through Paragraph IV certifications. Its principal position was that the relevant patent claims were invalid, including for obviousness. Mylan also disputed infringement to the extent necessary under the ANDA litigation framework.

The case placed the ’945 formulation patent at the center of the dispute. Bristol-Myers Squibb argued that the claimed apixaban composition was not an obvious modification of the prior art. Mylan argued that the formulation resulted from routine pharmaceutical development and that the prior art supplied a reason to combine known ingredients and concentration ranges.

What was the district court’s decision?

The District of Delaware ruled that the asserted claims of the ’945 patent were invalid as obvious. The court concluded that the prior art provided a motivation to develop the claimed apixaban formulation and that the claimed composition did not contain a sufficient inventive distinction over the prior art.

The obviousness analysis addressed the standard factors applied under Section 103 of the Patent Act:

1. The scope and content of the prior art.
2. Differences between the prior art and the asserted claims.
3. The level of ordinary skill in the pharmaceutical formulation field.
4. Objective indicia of nonobviousness, such as commercial success, unexpected results, and industry skepticism.

Bristol-Myers Squibb challenged the court’s assessment of the motivation to combine references and the weight given to objective evidence. The company maintained that the commercial formulation was not predictable from the prior art and that the formulation properties supported patentability.

The district court’s invalidity judgment removed the ’945 patent as a basis for blocking Mylan’s proposed generic product. The ruling did not, by itself, invalidate the separate ’208 compound patent.

How did the Federal Circuit resolve the appeal?

The Federal Circuit affirmed the district court’s judgment that the asserted ’945 patent claims were invalid as obvious. The appellate court held that the district court did not commit reversible error in its obviousness analysis. (Bristol-Myers Squibb Co. v. Mylan Pharmaceuticals Inc., 2023)

The Federal Circuit’s decision had three practical effects:

• It eliminated the ’945 patent as an enforceable formulation barrier against Mylan’s ANDA product.
• It confirmed that later-arriving formulation claims must show more than the selection of conventional excipients or predictable pharmaceutical parameters.
• It limited Bristol-Myers Squibb’s ability to rely on a secondary formulation patent to extend exclusivity after the core compound patent.

The decision did not create a general rule that all apixaban formulation patents were invalid. Its holding applied to the asserted claims and the record developed in that case.

What was the patent litigation timeline?

Date	Event
2016	Mylan filed an ANDA for generic apixaban tablets and submitted Paragraph IV certifications.
January 2017	Bristol-Myers Squibb filed Civil Action No. 1:17-cv-00055 in the District of Delaware.
2017-2021	The parties litigated infringement, validity, claim construction, expert testimony, and obviousness.
District court judgment	The court held the asserted ’945 claims invalid as obvious.
2022	The Federal Circuit appeal was docketed as No. 2022-2090.
June 16, 2023	The Federal Circuit affirmed the invalidity judgment.

The case is distinct from broader Eliquis patent disputes involving other generic applicants. Parallel actions, settlements, later Orange Book listings, and other patent rights may affect the launch position of a different ANDA applicant.

Did Mylan win a Paragraph IV challenge?

Yes. Mylan prevailed against the asserted ’945 formulation patent because the Federal Circuit affirmed the finding that the claims were invalid as obvious.

That result is narrower than a complete freedom-to-market determination. A Paragraph IV victory against one patent does not automatically resolve:

• Other Orange Book-listed patents.
• Unasserted formulation claims.
• Non-Orange Book manufacturing patents.
• Regulatory exclusivity.
• Product-specific settlement restrictions.
• Patent rights held by third parties.
• Litigation involving another generic applicant.

For Mylan, the decision materially improved the legal position of its ANDA. The commercial launch date still depended on the status of the remaining Eliquis patent estate and FDA approval conditions.

What was the Orange Book status of Eliquis?

The Orange Book identified Eliquis patent rights covering the apixaban active ingredient and pharmaceutical compositions. The ’208 compound patent and ’945 formulation patent represented two different layers of protection.

The ’208 patent was more commercially significant because it covered the active ingredient. The ’945 patent was an incremental formulation right, but its later expiration date gave it potential value as a follow-on barrier. The Federal Circuit’s invalidity decision removed that later patent from the enforceable exclusivity analysis for the claims at issue.

Orange Book status does not itself determine whether a generic can launch. A generic applicant must also account for FDA approval timing, 30-month stays, pediatric exclusivity, other patents, injunctions, and contractual restrictions.

How strong was the Eliquis patent estate after the decision?

The estate was mixed rather than uniformly strong.

Strengths

The ’208 patent had composition-of-matter scope and therefore represented a substantial barrier while enforceable. Compound patents are generally more difficult to design around than formulation patents because a generic product containing the same active ingredient falls within the claimed chemical subject matter.

Bristol-Myers Squibb and Pfizer also had significant commercial resources to litigate multiple ANDA challenges and negotiate settlements with generic applicants.

Weaknesses

The ’945 decision demonstrated vulnerability in the secondary formulation layer. The Federal Circuit accepted an obviousness theory based on predictable formulation development and prior-art teachings. That ruling reduced the value of the later-expiring patent as an independent launch barrier.

The decision also illustrates the risk of relying on routine pharmaceutical composition claims to extend market exclusivity. Claims directed to standard excipients, conventional tablet design, and predictable concentration ranges face heightened obviousness exposure when the prior art supplies a reason to make the claimed formulation.

Did the case involve a settlement agreement?

The reported Federal Circuit decision reflects an adjudicated appeal rather than a settlement-based disposition of the ’945 validity dispute. The public litigation record for this case should be distinguished from separate agreements between Bristol-Myers Squibb, Pfizer, and other generic apixaban applicants.

Settlement terms in Hatch-Waxman cases often include a licensed launch date, contingent entry rights, manufacturing restrictions, and provisions addressing future patent challenges. A settlement with one generic applicant does not establish the launch rights of every other ANDA filer.

What generic entry risks did the decision create?

The decision increased generic-entry risk in several ways.

First, it removed a later-expiring formulation patent from the case-specific enforcement portfolio. Second, it supplied generic applicants with a favorable Federal Circuit precedent on the obviousness of apixaban formulation claims. Third, it reduced settlement leverage because a generic applicant could point to an appellate invalidity decision when assessing litigation risk.

The remaining commercial risk centered on the ’208 compound patent, regulatory exclusivity, and any separate patent or settlement rights. A generic applicant that defeated the formulation patent but remained blocked by the compound patent would still face delayed entry.

How did the litigation affect Bristol-Myers Squibb and Pfizer revenue exposure?

Eliquis was one of the largest products in the Bristol-Myers Squibb and Pfizer portfolios. The loss of the ’945 patent did not immediately eliminate branded revenue because the compound patent and regulatory barriers remained relevant. It did, however, reduce the duration and depth of the patent-based exclusivity stack.

The principal financial exposure was a compressed post-compound-patent launch window. If multiple generic manufacturers received FDA approval and obtained launch rights near the expiration of the remaining core patent, Eliquis could face rapid price erosion and volume migration. Anticoagulant products are particularly exposed to multi-source generic competition because substitution can occur across a large treated population once pharmacy-level generic availability begins.

Key Takeaways

• Bristol-Myers Squibb sued Mylan in Delaware over Mylan’s ANDA for generic apixaban tablets.
• The main appellate patent was U.S. Patent No. 9,326,945, covering apixaban pharmaceutical compositions.
• The district court held the asserted ’945 claims invalid as obvious.
• The Federal Circuit affirmed on June 16, 2023.
• The decision removed the ’945 patent as an effective litigation barrier against Mylan’s proposed product.
• The separate ’208 apixaban compound patent remained commercially important.
• The case did not establish that every Eliquis patent was invalid or that every generic applicant could launch immediately.
• The ruling weakened Bristol-Myers Squibb’s formulation-patent strategy and increased generic-entry pressure as core compound protection approached expiration.

FAQs

What was Bristol-Myers Squibb v. Mylan Pharmaceuticals about?

It was a Hatch-Waxman patent case concerning Mylan’s proposed generic version of Eliquis, the apixaban anticoagulant.

Which Eliquis patent did Mylan defeat?

Mylan defeated the asserted claims of U.S. Patent No. 9,326,945. The Federal Circuit affirmed that those claims were invalid as obvious.

Did Mylan invalidate the main apixaban compound patent?

No. The Federal Circuit decision addressed the asserted formulation patent in the appeal. It did not invalidate the separate ’208 compound patent.

Did the ruling authorize immediate generic Eliquis launch?

No. The decision removed one patent barrier but did not independently resolve FDA approval timing, remaining patents, pediatric exclusivity, injunctions, or settlement restrictions.

Why was the ’945 patent commercially important?

The ’945 patent was designed to protect the marketed apixaban tablet formulation after the core compound patent. Its invalidity reduced the duration and strength of the Eliquis patent estate.

References

Bristol-Myers Squibb Co. v. Mylan Pharmaceuticals Inc., No. 1:17-cv-00055-RGA, U.S. District Court for the District of Delaware.

Bristol-Myers Squibb Co. v. Mylan Pharmaceuticals Inc., No. 2022-2090, 69 F.4th 1368 (Fed. Cir. 2023).

U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. Orange Book.

U.S. Patent and Trademark Office. (2005). U.S. Patent No. 6,967,208: Lactam-containing compounds and derivatives thereof.

U.S. Patent and Trademark Office. (2016). U.S. Patent No. 9,326,945: Pharmaceutical compositions comprising apixaban.